1	Immunity to non-dengue flaviviruses impacts dengue virus IgG ELISA specificity in Cambodia
2	
3	Camila Odio ¹ , Christina Yek ^{2, 3*} , Chloe M. Hasund ^{1*} , Somnang Man ² , Piseth Ly ² , Sreynik
4	Nhek ² , Sophana Chea ² , Chanthap Lon ² , Charlie Voirin ¹ , Rekol Huy ⁴ , Rithea Leang ⁴ , Chea
5	Huch ⁴ , L. Fabiano Oliveira ^{2, 3} , Jessica E. Manning ^{2, 3,+} , Leah C. Katzelnick ^{1,+}
6	
7	Affiliations: ¹ Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases,
8	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
9	MD 20892, USA, ² International Center of Excellence in Research, National Institute of Allergy
10	and Infectious Diseases, National Institutes of Health, Phnom Penh, Cambodia, ³ Laboratory of
11	Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National
12	Institutes of Health, Bethesda, MD 20892, ⁴ National Center for Parasitology, Entomology, and
13	Malaria Control, Ministry of Health, Phnom Penh, Cambodia.
14	
15	*Authors made equal contributions to this manuscript.
16	
17	⁺ Corresponding authors:
18	
19	Leah Katzelnick PhD MPH
20	Chief, Viral Epidemiology and Immunity Unit
21	National Institutes of Allergy and Infectious Diseases, National Institutes of Health
22	Building 33, Room 3W10A, 33 North Drive
23	Bethesda, MD 20892-3203

- 24 Phone: 240-627-3276, Email: <u>leah.katzelnick@nih.gov</u>
- 25
- 26 Jessica Manning MD MSc
- 27 Director, International Center of Excellence in Research CAMBODIA
- 28 National Institutes of Allergy and Infectious Diseases, National Institutes of Health
- 29 Email: jess.manning@gmail.com
- 30

32 Abstract 92 words

33	Seroprevalence studies are the gold standard for disease surveillance, and serology was used to
34	determine eligibility for the first licensed dengue vaccine. However, expanding flavivirus
35	endemicity, co-circulation, and vaccination complicate serology results. Among 713 healthy
36	Cambodian children, a commonly used indirect dengue virus IgG ELISA (PanBio) had a lower
37	specificity than previously reported (94% vs. 100%). Of those with false positive PanBio results,
38	46% had detectable neutralizing antibodies against other flaviviruses, with the highest frequency
39	against West Nile virus (WNV). Immunity to non-dengue flaviviruses can impact dengue
40	surveillance and potentially pre-vaccine screening efforts.
41	
42	Manuscript: 1,696 words
43	Background
44	The genus Orthoflavivirus includes multiple pathogenic mosquito-borne viruses including
45	dengue viruses 1-4 (DENV1-4), Japanese encephalitis virus (JEV), West Nile virus (WNV), Zika
46	virus (ZIKV) and yellow fever virus (YFV) [1]. With expanding vector habitats, known
47	flaviviruses are rising in global incidence, and novel flaviviruses are emerging [2, 3]. These
48	flaviviruses commonly co-circulate, and the antibodies induced by one exposure may cross-react
49	with others in the genus [4]. Additionally, affected areas use vaccines to protect against JEV and
50	YFV, further complicating serology. As flaviviruses expand their range and vaccination
51	increases, differentiating true exposure from cross-reactivity is not only difficult, but also
52	increasingly important to guide diagnostic, preventative, and therapeutic measures.
53	

54 Accurately characterizing population level immunity to DENV is important for current dengue 55 vaccination efforts. Dengvaxia (Sanofi Pasteur), the first widely approved dengue vaccine, was 56 originally recommended in 2016 by the World Health Organization (WHO) Strategic Advisory 57 Group of Experts (SAGE) panel for use in areas with \geq 70% DENV seroprevalence in children 58 age 9 and older, with seroprevalence most often measured using common IgG ELISAs [5]. When 59 it was later shown that Dengvaxia increases the risk of severe disease in DENV-naïve 60 individuals, the WHO recommended use of highly specific individual-level testing of DENV 61 immunity to confirm vaccine eligibility, as well as use in high-risk populations in endemic areas 62 [6][7]. The World Health Organization has since recommended that the second licensed dengue vaccine QDENGA (Takeda) be introduced to children aged 6 to 16 years, also in highly endemic 63 64 areas [8]. Given the lack of observed vaccine-induced protection against DENV3 in seronegative individuals and the unknown protection against DENV4 [9], a strategy based on population-level 65 66 estimates of endemicity has the potential to increase disease risk for seronegative individuals. 67 Population-level serosurveys for DENV conducted for surveillance purposes generally use 68

69 commercial IgG ELISAs. The plaque reduction neutralization test (PRNT), which measures 70 neutralizing antibodies (nAbs) to DENV, is considered the gold standard for evaluating 71 specificity but requires intensive and specialized labor. The PanBio indirect DENV IgG ELISA 72 (Abbott, Brisbane, QLD, Australia) is one of the most commonly used assays for measuring 73 DENV immunity, and the manufacturer reports 100% specificity based on 108 DENV-naïve 74 individuals from endemic areas [10]. Separate work demonstrated 99% specificity of this ELISA 75 using DENV1-4 PRNT₅₀≥10 as the standard for DENV immunity in a cohort of 534 individuals 76 from both the USA and dengue-endemic regions before 2016 [11]. However, the PanBio indirect

77	DENV IgG ELISA yields higher false positivity rates when evaluated with individuals positive
78	to other flaviviruses, including those who had received an inactivated JEV vaccine (3%), or had
79	immunity against ZIKV (34%) or WNV (51%) [11]. The degree to which immunity to other
80	flaviviruses affects DENV serosurveys is dependent on the site, and a major challenge is that the
81	extent of circulation of other flaviviruses is often unknown. For instance, an observational study
82	of children aged 9-14 years in the Philippines in 2017 used a PRNT ₇₀ ≥40 as the indicator of
83	DENV immunity and reported a relatively low ELISA specificity, of 93.4%. Of the false positive
84	samples, 64% had nAb against ZIKV or JEV, in a region where ZIKV was not thought to be
85	widespread. Thus, although the PanBio ELISA has a reportedly high specificity, this number
86	may vary with flavivirus cross-reactivity and expanding co-circulation or vaccination.
87	
88	Here, we examine the performance of the PanBio ELISA in young children in Cambodia, a
89	highly dengue-endemic area. ZIKV was recently found to co-circulate in the area, and JEV is
90	endemic. JEV vaccination campaigns with a live-attenuated JEV vaccine SA14-14-2 started
91	around 2014, and WNV nAb have been identified in birds but not humans [12-15].
92	
93	
94	Methods
95	The study protocol was approved by the institutional review boards at the US National Institutes
96	of Health and the National Ethics Committee on Human Research in Cambodia. The guardians
97	of all pediatric participants provided signed informed consent to participate in the study.
98	Between July and August of 2018, 771 children aged 2-9 years living in Kampong Speu,
99	Cambodia were enrolled in a prospective longitudinal cohort (NCT03534245) [16]. At entry, the

100	PanBio indirect DENV IgG ELISA was performed on sera from 770 individuals. For the 273
101	participants with ELISA values >1.1 (defined as DENV positive by the manufacturer), PRNTs
102	were performed using clinical isolates of DENV1-4 [17]. All PRNTs were performed on Vero
103	cells, as described previously, starting at a serum dilution of 1:5 followed by the addition of an
104	equal volume of virus. Thus, the lower limit of detection was a dilution of 1:10 [18]. The nAb
105	titer was defined as the reciprocal of the calculated dilution wherein virus infectivity was reduced
106	by 50% (PRNT ₅₀). PRNT ₅₀ ≥1:10 (reported as PRNT ₅₀ ≥10) against any DENV serotype was
107	considered immune to that serotype. To assess for non-dengue flavivirus nAbs, PRNTs were
108	performed using the following strains: ZIKV-PARAIBA/2015, a chimeric vaccine candidate,
109	WNV/DEN4Δ30 [19], and JEV vaccine strain SA14-14-2 (Figure 1A-B). Consistent with prior
110	classifications, seropositivity to any non-dengue flavivirus was defined as PRNT ₅₀ \geq 10 [20-22].
111	Statistical comparisons were done in RStudio for macOS (2022.07.1, Build 554) using tidyverse
112	and gtsummary packages. Heatmaps were generated in PRISM (v.9 for macOS).
112	

113

114 Results

Of the 770 individuals, n=440 had ELISA<0.2 and were considered DENV naïve per work 115 116 confirming a strong correlation between ELISA<0.2 and negative PRNT [23]. Fifty-seven 117 individuals were excluded: 44 had ELISA values between 0.2-0.9 without a confirmatory PRNT 118 and 13 had ELISA values between 0.9-1.1, which the manufacturer considers equivocal 119 immunity. Of the 273 individuals with ELISA>1.1, n=28 were DENV negative by PRNT ('false 120 positive'), n=245 were DENV positive ('immune'), and there were no false negatives, resulting in a 100% sensitivity and 94% specificity of the ELISA assay. Comparison of the naïve, false 121 122 positive, and immune groups revealed that both the mean age and ELISA value of the false

positive group fell between those of the naïve and immune groups (p<0.001, Table 1A). Over the
two years of surveillance, there were few PCR-confirmed cases of symptomatic dengue (n=46)
with no differences in frequency among groups (p=0.7).

126

127 We hypothesized that the discordance between the DENV ELISA IgG and PRNT results could

128 be due to cross-reactivity against non-dengue flaviviruses. To test this, we compared the

129 frequencies of nAbs against JEV, ZIKV, and WNV in the false positive individuals versus n=50

130 randomly chosen naïve individuals (Figure 1A-B). Consistent with prior classifications,

131 seropositivity was defined as PRNT₅₀ \geq 10 [20-22]. Overall, 46% of the false positive group had

132 PRNT₅₀ \geq 10 against \geq 1 other flavivirus versus 20% of the naive group (p=0.020, Table 1B).

133 Although the false positive group had higher percentages of individuals with positive JEV and

134 ZIKV nAbs, only WNV nAbs were significantly more common than in the naïve group (0% vs.

135 25%, p<0.001). To further assess these trends, we tested n=21 individuals with DENV

136 ELISA>1.1 and DENV PRNT between 10-20 (Figure 1). This group has low DENV nAbs and

has been considered DENV negative in other work [16, 23]. When compared to the false positive

138 group, the low DENV nAb group had similar frequencies of JEV, ZIKV, and WNV nAb ($p \ge 0.4$

139 for all three nAbs, Table 1B). Thus, immunity to other flaviviruses may contribute to high

140 ELISA values in individuals with undetectable and low DENV nAbs.

141

142 To help identify the primary exposure in the 13 individuals with PRNT₅₀ \geq 10 against \geq 2

143 flaviviruses, PRNT₉₀ titers were calculated [4]. Of these, n=4 had PRNT₉₀<10 against all 4

144 flaviviruses, and n=3 had PRNT₉₀ \geq 10 to multiple flaviviruses: n=2 to JEV and WNV, n=1 to

JEV, WNV, and ZIKV (Figure 1C-D). Six individuals had PRNT₉₀≥10 against only 1 flavivirus:

146	n=1 to ZIKV, n=3 to JEV, and n=2 to WNV. Of the two individuals with $PRNT_{90}\geq 10$ against
147	WNV only, one had received a JEV vaccine and had a PRNT ₅₀ ≥10 against JEV and one had
148	PRNT ₅₀ ≥10 against ZIKV. While the PRNT ₉₀ ≥10 against WNV only suggests a primary WNV
149	infection, it is possible that JEV vaccination and ZIKV primary exposure induced highly cross-
150	reactive WNV nAb [24]. There were also two individuals with low DENV nAb and PRNT ₅₀ \geq 10
151	against WNV only. Although these individuals did not have PRNT ₉₀ ≥10 against DENV or
152	WNV, one had WNV titer that was 2-fold higher than DENV titer. Again, this finding is
153	suggestive of primary WNV infection, but cross-reactivity after DENV exposure cannot be ruled
154	out. Regardless of the WNV nAb source, this immunity was common and likely central to the
155	decreased ELISA specificity observed.
156	
157	Discussion
157 158	Discussion We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in
158	We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in
158 159	We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb
158 159 160	We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb with potential contributions by ZIKV and JEV nAb. Notably, JEV vaccination can induce WNV
158 159 160 161	We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb with potential contributions by ZIKV and JEV nAb. Notably, JEV vaccination can induce WNV cross-reactivity [25], and it is possible that the WNV nAb were induced by JEV vaccination or
158 159 160 161 162	We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb with potential contributions by ZIKV and JEV nAb. Notably, JEV vaccination can induce WNV cross-reactivity [25], and it is possible that the WNV nAb were induced by JEV vaccination or infection. Alternatively, the WNV nAbs may represent true WNV exposure, underlining the need
158 159 160 161 162 163	We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb with potential contributions by ZIKV and JEV nAb. Notably, JEV vaccination can induce WNV cross-reactivity [25], and it is possible that the WNV nAb were induced by JEV vaccination or infection. Alternatively, the WNV nAbs may represent true WNV exposure, underlining the need for ongoing vigilance for WNV circulation in humans in Cambodia. Additionally, half of the
158 159 160 161 162 163 164	We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb with potential contributions by ZIKV and JEV nAb. Notably, JEV vaccination can induce WNV cross-reactivity [25], and it is possible that the WNV nAb were induced by JEV vaccination or infection. Alternatively, the WNV nAbs may represent true WNV exposure, underlining the need for ongoing vigilance for WNV circulation in humans in Cambodia. Additionally, half of the false positive results remained unexplained, potentially due to waning immunity or infection by

168 co-circulation and vaccination could increasingly impact serology results. Serosurveys conducted

169	for vaccination campaigns to identify populations where dengue is endemic may overestimate
170	dengue burden as a result of false positivity due to infection or vaccination with other
171	flaviviruses. Such population-based strategies are of particular concern when identifying target
172	populations for dengue vaccines where safety in DENV seronegative individuals has not yet
173	been confirmed. Adverse events in these individuals could greatly impact vaccine trust and
174	uptake, as occurred with Dengvaxia [26]. For vaccines that are known to be unsafe in
175	seronegative individuals like Dengvaxia, pre-vaccination screening is required to determine
176	vaccine eligibility, which allows individuals to make informed decisions about their own vaccine
177	risk and benefit. It is recommended that past infection be confirmed either by virological assay
178	or by two specific serological assays, such as the anti-DENV1-4 NS1 ELISA IgG and a IgG
179	rapid test [7]. Evaluation of false positivity due to infection with other emerging flaviviruses is
180	critical to ensuring the safety of this screening approach.
181	
182	Overall, our study demonstrates that the PanBio IgG ELISA and even PRNT results should be
183	interpreted with caution in areas with flavivirus co-circulation and vaccines, and multiple tests
184	may be required to confirm DENV seroprevalence.
185	
186	






Figure 1. Neutralizing antibody titers against DENV, JEV, WNV, ZIKV in individuals who
were false positive (ELISA>1.1, DENV PRNT₅₀<10), naïve (ELISA<0.2), or had low DENV
nAb (ELISA>1.1, DENV PRNT₅₀ of 10-20) as measured by PRNT₅₀ (A-B) and PRNT₉₀ titers
(C-D). PRNT₉₀ titers were only measured in those with nAb against ≥2 non-dengue flaviviruses.

201	Table 1. Characteristics and immune profiles of individuals who were naïve (ELISA<0.2), false
202	positive (ELISA>1.1, PRNT ₅₀ <10), or DENV immune (ELISA>1.1, PRNT ₅₀ ≥10). The presence
203	of neutralizing antibodies against non-dengue flaviviruses were compared in the naïve and false
204	positive groups and between the false positive and the low DENV immune group (ELISA>1.1,
205	PRNT ₅₀ 10-20).

206 A. Cohort characteristics

Characteristics	Naïve	False positive	Immune (n=245)	p-value [†]
	(n=440)*	(n=28)		
Age	4.9 (2.0)	6.0 (2.2)	6.8 (2.2)	< 0.001
Sex				0.2
Female	230 (52)	10 (36)	126 (51)	
Male	210 (48)	18 (64)	119 (49)	
ELISA IgG value	0.03 (0.04)	2.00 (0.72)	2.92 (0.84)	< 0.001
Dengue case				0.7
No dengue	321 (91)	22 (92)	156 (93)	
Symptomatic	32 (9)	2 (8)	12 (7)	
dengue				
Unknown [‡]	87	4	77	

207

208 B. Immunity subset analysis

Immunity	Naïve	p-value§	False positive	p-value [¶]	Low DENV nAb
profile	(n=50)		(n=28)		(n=21)
JEV nAb		0.058		0.4	

Negative	41 (82)		17 (61)		16 (76)
Positive	9 (18)		11 (39)		5 (24)
ZIKV nAb		0.3		0.4	
Negative	48 (96)		25 (89)		17 (81)
Positive	2 (4)		3 (11)		4 (19)
WNV nAb		< 0.001		0.5	
Negative	50 (100)		21 (75)		14 (67)
Positive	0 (0)		7 (25)		7 (33)
≥1 Flavivirus	10 (20)	0.020	13 (46)	>0.9	10 (48)
positive					
≥2 Flavivirus	1 (2)	0.003	7 (25)	>0.9	5 (24)
positive					

209

210 *Mean (SD) or no. (%)

- [†]One-way ANOVA, Pearson's Chi-squared test; Fisher's exact test
- ²¹² [‡]Unknown indicates that participant was lost to follow-up prior to final study visit at 24 months
- 213 [§]Fisher's exact test comparing naïve vs. false positive group.
- ¹Fisher's exact test comparing false positive group vs. low DENV nAb group.

215 Dengue virus, DENV; Japanese encephalitis virus, JEV; neutralizing antibodies, nAb; West Nile

216 virus, WNV; Zika virus, ZIKV

217

219	Acknowledgements: The authors would like to thank Patrick Mpingabo for his support					
220	establishing ELISA assays to evaluate samples for antibodies against the nonstructural-1 proteins					
221	of JEV, ZIKV, and WNV. These assays were not ultimately used in the manuscript. We would					
222	also like to thank Kelsey Lowman for her support completing the WNV and JEV PRNT assays.					
223						
224	Funding: This research was supported by the Intramural Research Program at the National					
225	Institute of Allergy and Infectious Diseases.					
226						
227	Conflict of Interest: The authors declare no conflict of interest.					
228						
229	This work was presented as a poster at the American Society of Tropical Medicine and Hygeine					
230	annual conference in October 2023.					
231						
232	References					
233	1. Postler TS, Beer M, Blitvich BJ, et al. Renaming of the genus Flavivirus to Orthoflavivirus					
234	and extension of binomial species names within the family Flaviviridae. Archives of Virology					
235	2023 ; 168:224.					
236	2. Du M, Jing W, Liu M, Liu J. The Global Trends and Regional Differences in Incidence of					
237	Dengue Infection from 1990 to 2019: An Analysis from the Global Burden of Disease Study					
238	2019. Infectious Diseases and Therapy 2021; 10:1625-43.					
239	3. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nature					
240	Microbiology 2020 ; 5:796-812.					

- 241 4. Chan KR, Ismail AA, Thergarajan G, et al. Serological cross-reactivity among common
- flaviviruses. Front Cell Infect Microbiol **2022**; 12:975398.
- 243 5. Secretariat SWGoDVaWHO. Background paper on dengue vaccines. Available at:
- 244 https://terrance.who.int/mediacentre/data/sage/SAGE Docs Ppt Apr2016/10 session dengue/A
- 245 pr2016 session10 dengue vaccines.pdf. Accessed 11/17/2023.
- 6. WHO. Dengue vaccine: WHO position paper. Weekly epidemiological record 2018; 93:457-
- **247** 76.
- 248 7. Prevention CfDCa. Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue
- 249 Vaccine. Available at: <u>https://www.cdc.gov/dengue/vaccine/hcp/testing.html</u>. Accessed October
- **250** 31 2023.
- 8. Takeda. Takeda's Dengue Vaccine Recommended by World Health Organization Advisory
- 252 Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to
- 253 16 Years. Available at: <u>https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Dengue-</u>
- 254 Vaccine-Recommended-by-World-Health-Organization-Advisory-Group-for-Introduction-in-
- 255 <u>High-Dengue-Burden-and-Transmission-Areas-in-Children-Ages-Six-to-16-Years</u>/. Accessed
- 256 October 31 2023.
- 257 9. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda's Dengue
- 258 Vaccine Candidate (TAK-003). Clinical Infectious Diseases 2021.
- 259 10. Abbott. Panbio[™] DENGUE IgG CAPTURE ELISA. Available at:
- 260 <u>https://www.globalpointofcare.abbott/au/en/product-details/panbio-dengue-igg-capture-</u>
- 261 <u>elisa.html</u>. Accessed August 29 2023.

- 262 11. Bonaparte M, Zheng L, Garg S, et al. Evaluation of rapid diagnostic tests and conventional
- 263 enzyme-linked immunosorbent assays to determine prior dengue infection. J Travel Med **2019**;

264 26.

- 265 12. Yek C, Li Y, Pacheco AR, et al. National dengue surveillance, Cambodia 2002-2020. Bull
- 266 World Health Organ **2023**; 101:605-16.
- 13. Duong V, Ong S, Leang R, et al. Low Circulation of Zika Virus, Cambodia, 2007-2016.
- 268 Emerg Infect Dis 2017; 23:296-9.
- 269 14. Horwood PF, Duong V, Laurent D, et al. Aetiology of acute meningoencephalitis in
- 270 Cambodian children, 2010-2013. Emerg Microbes Infect 2017; 6:e35.
- 15. Auerswald H, Ruget AS, Ladreyt H, et al. Serological Evidence for Japanese Encephalitis
- and West Nile Virus Infections in Domestic Birds in Cambodia. Front Vet Sci 2020; 7:15.
- 273 16. Manning JE, Chea S, Parker DM, et al. Development of Inapparent Dengue Associated With
- 274 Increased Antibody Levels to Aedes aegypti Salivary Proteins: A Longitudinal Dengue Cohort in
- 275 Cambodia. The Journal of Infectious Diseases 2021.
- 17. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live
- 277 dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
- 278 Am J Trop Med Hyg **2001**; 65:405-13.
- 279 18. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and
- validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to
- four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med
- **282** Hyg **2013**; 88:962-70.

- 283 19. Pierce KK, Whitehead SS, Kirkpatrick BD, et al. A Live Attenuated Chimeric West Nile
- 284 Virus Vaccine, rWN/DEN4∆30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older
- Adult Volunteers. The Journal of Infectious Diseases **2016**; 215:52-5.
- 286 20. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;
- 287 17:1055-65.
- 288 21. Sornjai W, Jaratsittisin J, Auewarakul P, Wikan N, Smith DR. Analysis of Zika virus
- neutralizing antibodies in normal healthy Thais. Sci Rep **2018**; 8:17193.
- 290 22. Kaiser JA, Barrett ADT. Twenty Years of Progress Toward West Nile Virus Vaccine
- 291 Development. Viruses 2019; 11.
- 292 23. Lopez AL, Adams C, Ylade M, et al. Determining dengue virus serostatus by indirect IgG
- 293 ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a
- prospective population-based study. The Lancet Global Health **2021**; 9:e44-e51.
- 295 24. Hou B, Chen H, Gao N, An J. Cross-Reactive Immunity among Five Medically Important
- 296 Mosquito-Borne Flaviviruses Related to Human Diseases. Viruses 2022; 14:1213.
- 297 25. Mansfield KL, Horton DL, Johnson N, et al. Flavivirus-induced antibody cross-reactivity. J
- **298** Gen Virol **2011**; 92:2821-9.
- 299 26. Larson HJ, Hartigan-Go K, de Figueiredo A. Vaccine confidence plummets in the
- 300 Philippines following dengue vaccine scare: why it matters to pandemic preparedness. Hum
- 301 Vaccin Immunother 2019; 15:625-7.